Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Ontario Institute for Cancer Research makes three equity investments

Abstract:
Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research (OICR) today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.

Ontario Institute for Cancer Research makes three equity investments

Ontario, Canada | Posted on April 26th, 2010

"These technologies hold exceptional promise in the advancement of personalized cancer medicine," said Mr. Stonebanks. "The investments will help close the gap between seed funding and clinical proof of concept, moving these programs closer to the commercial arena."

"The OICR has quickly established itself as a global leader in research commercialization," said John Milloy, Ontario Minister of Research and Innovation. "The Ontario government continues to support OICR as it invests in health technologies and strengthens Ontario as an innovation-based economy and society."

Dr. Li Zhang, Senior Scientist in the Division of Cellular and Molecular Biology at the University Health Network's Toronto General Research Institute, received the investment for her novel cellular immunotherapy for cancer.

OICR and the University Health Network created a new spin-off company to complete the pre-clinical requirements to test Dr. Zhang's novel cellular therapy in patients with acute myeloid leukemia (AML), a disease which has seen few improvements in therapy in the last 40 years. This proprietary UHN technology involves the growth of a specific minor population of the patient's own cancer-killing T cells in the laboratory with subsequent reinfusion into the patient to fight their disease. Dr. Zhang's group has performed extensive pre-clinical testing of these cancer-killing cells grown from AML patients and has shown that they kill human leukemia cells in an animal model. The next step is a phase I clinical trial in AML patients.

DVS Sciences Inc., a spin-off company from the University of Toronto, will use OICR's investment to support further engineering and product development of its revolutionary instrument for highly multiplexed biomarker analysis for scientific research, clinical trials and personalized medicine. The machine is similar to a flow cytometer but instead of fluorescent tags, which limit the multiplex capacity due to spectral overlap, the DVS system uses stable isotope tags to identify up to 100 biomarkers at a time with very high resolution and dynamic range. The system has been demonstrated analyzing 30 biomarkers simultaneously in single human leukemia cells at a rate of 1,000 cells per second with absolute signal quantification. Several prototypes have been sold to top laboratories in the U.S.A. and Canada. Also under development by DVS is a low-cost liquid bead array for gene analysis with multiplex capability in the hundreds of thousands - far beyond that of today's fluorescent-based bead arrays and approaching that of "gene chip" microarrays but at a fraction of the cost.

Dr. Shana Kelley, Director of the Division of Biomolecular Sciences in the Faculty of Pharmacy at the University of Toronto and Dr. Ted Sargent, Professor in the Edward S. Rogers Sr. Department of Electrical and Computer Engineering at the University of Toronto, and Canada Research Chair in Nanotechnology, received an investment for their validation of a microchip-based diagnostic system for clinically accepted leukemia biomarkers.

Plans are being made for the technology to be advanced by a start-up company with seed funding coming from OICR and other groups. OICR's investment will facilitate testing and refinement of the sensitive electronic chip and hand-held device for direct and rapid detection of clinically relevant biomolecules in patient samples. The chip-based system uses no enzymatic amplification steps and provides electronic detection of biomolecules (DNA, RNA or protein) in five minutes with high specificity and at concentrations as low as 100 molecules per sample. The single-use detector chips feature simple, inexpensive silicon-based integrated circuit technology, multiplex and multiple sample type capability, and integrated sample pre-processing.

OICR had previously invested in the three projects through its Intellectual Property Development and Commercialization Program, which provides seed funding for late stage academic projects that meet specific market-oriented criteria.

####

About Ontario Institute for Cancer Research
OICR is a new, innovative cancer research & development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation funded by the Government of Ontario through the Ministry of Research and Innovation. OICR supports 500 scientific staff and trainees (located at its headquarters and in research institutes and academia across the Province of Ontario) and an $85 million annual operating budget. It has key research efforts underway in small molecules, biologics, cancer stem cells, imaging, genomics, informatics and bio-computing, from early stage research to Phase I clinical trials.

OICR is making Ontario more effective in knowledge transfer and commercialization, to maximize health and economic benefits of research findings for the people of Ontario. For more information, please visit the website at www.oicr.on.ca/commercialization.

For more information, please click here

Contacts:
Rhea Cohen
Director of Communications

Telephone: (416) 673-6642
Mobile: (416) 671-2846

Copyright © Newswire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016

Tokyo Institute of Technology research: 3D solutions to energy savings in silicon power transistors December 6th, 2016

Physicists decipher electronic properties of materials in work that may change transistors December 6th, 2016

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

Govt.-Legislation/Regulation/Funding/Policy

Physicists decipher electronic properties of materials in work that may change transistors December 6th, 2016

Construction of practical quantum computers radically simplified: Scientists invent ground-breaking new method that puts quantum computers within reach December 5th, 2016

Shape matters when light meets atom: Mapping the interaction of a single atom with a single photon may inform design of quantum devices December 4th, 2016

Research Study: MetaSOLTM Shatters Solar Panel Efficiency Forecasts with Innovative New Coating: Coating Provides 1.2 Percent Absolute Enhancement to Triple Junction Solar Cells December 2nd, 2016

Academic/Education

Oxford Nanoimaging report on how the Nanoimager, a desktop microscope delivering single molecule, super-resolution performance, is being applied at the MRC Centre for Molecular Bacteriology & Infection November 22nd, 2016

The University of Applied Sciences in Upper Austria uses Deben tensile stages as an integral part of their computed tomography research and testing facility October 18th, 2016

Enterprise In Space Partners with Sketchfab and 3D Hubs for NewSpace Education October 13th, 2016

New Agricultural Research Center Debuts at UCF October 12th, 2016

Investments/IPO's/Splits

Harris & Harris Group Issues Letter to Shareholders and Information for Shareholder Call on Tuesday, November 15, 2016 November 14th, 2016

Harris & Harris Group Issues Business Update and Reports Financial Statements as of September 30, 2016 November 9th, 2016

Forge Nano raises $20 million in Series A Funding: Nano coating technology innovator Forge Nano will use funding to expand manufacturing capacity and grow Lithium-Ion battery opportunities November 3rd, 2016

Harris & Harris Group Notes Announcements by Its Portfolio Companies During the Third Quarter of 2016 September 30th, 2016

Nanomedicine

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

Announcements

Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016

Tokyo Institute of Technology research: 3D solutions to energy savings in silicon power transistors December 6th, 2016

Physicists decipher electronic properties of materials in work that may change transistors December 6th, 2016

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

Nanobiotechnology

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

From champagne bubbles, dance parties and disease to new nanomaterials: Understanding nucleation of protein filaments might help with Alzheimer's Disease and type 2 Diabetes November 24th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project